Umashankar M.S

  In the present investigation an attempt was made to formulate fast dissolving tablets using BCS class II drug Repaglinide, ie low solubility and high permeability to form an inclusion complex to improve the dissolution rate, thus enhancing the bioavailability. Beta-CD inclusion complex was made in varying ratios 1:1, 1:3 and 1:5 of drug and polymer by solvent evaporation method. The complexes were evaluated for phase solubility, drug content and drug release. Phase solubility study revealed AL type indicating linear increase in solubility with increase in the carrier concentrations. The inclusion complex 1:1 ratio prepared by spray dried was studied for drug content uniformity which was ranging from 85-98%, FTIR showed no any compatibility of the drug and beta-CD; DSC and XRD showed distinct loss of drug crystallinity accounting for enhancement in the dissolution rate. SEM revealed spherical shape of the inclusion complex. The drug release study was carried out in 0.1N HCL using USP type paddle dissolution apparatus revealed to be 93% within 5 mins. The FDT was formulated by direct compression method six batches of tablets were prepared with varying ratios of superdisintegrants (F1-F6). The tablets were evaluated for hardness, friability, weight variation, disintegration which was found within the official range, drug content ranging from 89-94%. The formulation F3 containing Crosspovidone was optimized which showed maximum drug release of 98% within 10 mins. Kinetics of drug release from all the tablets followed zero order release with non-Fickian type diffusion. Key words: Repaglinide, Beta- Cyclodextrin, Spray drying and fast dissolving tablets

In this present work Erythromycin stearate nanosuspension has been formulated. Since Erythromycin stearate is insoluble in water, it has been formulated as nanosuspension to improve bioavailability of the drug. The formulation was carried out using High Pressure Homogenization method using different variables like drug-surfactants ratio, stirring speed and rotation time, to optimize the final formulation while keeping the quantities of active ingredient constant. An optimized final formulation was prepared by using drug, poloxamer 188 and tween20 in 1:2:2 ratios with stirring speed of 25000 rpm for 25 minutes using High Pressure Homogenizer (Polytron PT 1600E) followed by lyophilisation. The optimized final formulation was subjected to in-vitro parameters such as compatibility, drug content, particle size analysis, zeta-potential, SEM, in-vitro release profile. All the in vitro evaluation parameters complied the limits. Stability studies were also conducted as per ICH guidelines and from the result it may be concluded that the optimized formulation is stable. Finally, it is concluded that the drug is compatible and stable with the excipients, hence Erythromycin stearate can be formulated as nanosuspension by this method. Key words: Erythromycin stearate, Poloxamer 188, Nanosuspension, Zeta potential, DSC, SEM.